申请人:University of Georgia Research Foundation, Inc.
公开号:US20010036930A1
公开(公告)日:2001-11-01
Pharmaceutical prodrug compositions are provided comprising azide derivatives of drugs which are capable of being converted to the drug in vivo. Azide derivatives of drugs having amine, ketone and hydroxy substituents are converted in vivo to the corresponding drugs, increasing the half-life of the drugs. In addition azide prodrugs are often better able to penetrate the blood-brain barrier than the corresponding drugs. Especially useful are azide derivatives of cordycepin, 2′-F-ara-ddI, AraA, acyclovir, penciclovir and related drugs. Useful azide prodrugs are azide derivatives of therapeutic alicyclic amines, ketones, and hydroxy-substituted compounds, including aralkyl, heterocyclic aralkyl, and cyclic aliphatic compounds, where the amine or oxygen moiety is on the ring, or where the amine or oxygen moiety is on an aliphatic side chain, as well as therapeutic purines and pyrimidines, nucleoside analogs and phosphorylated nucleoside analogs.
提供了药物前药组成物,其中包括具有可在体内转化为药物的药物的偶氮衍生物。具有胺基,酮基和羟基取代基的药物的偶氮衍生物在体内转化为相应的药物,增加了药物的半衰期。此外,偶氮前药通常比相应的药物更能穿过血脑屏障。特别有用的是cordycepin,2'-F-ara-ddI,AraA,acyclovir,penciclovir和相关药物的偶氮衍生物。有用的偶氮前药是治疗性脂环烷胺,酮和羟基取代化合物的偶氮衍生物,包括芳基烷基,杂环芳基烷基和环状脂肪族化合物,其中胺基或氧原子基团位于环上,或胺基或氧原子基团位于脂肪侧链上,以及治疗性嘌呤和嘧啶,核苷类似物和磷酸化核苷类似物。